X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Active Ingredient Identification Made Faster Via UHPT Method

Content Team by Content Team
22nd July 2023
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

In the late 1950s and 1960s, thalidomide, a drug given to pregnant women to alleviate morning sickness, caused a tragic outcome. Over 12,000 babies were born with severe malformations, like shortened limbs, due to the drug’s side effects. These deformities were caused by the drug’s racemic mixture of two mirror-image forms. Understanding the molecular structures of compounds is vital for comprehending biological processes and developing effective drugs. Nuclear magnetic resonance spectroscopy (NMR) plays a significant role in this research by interpreting frequency signals. However, until recently, selectively measuring carbon nuclei signals associated with specific hydrogen atoms in a single measurement posed a challenge.

However, there is good news. Doctors in Korea have introduced a groundbreaking NMR method called the ultraselective heteronuclear polarization transfer method (UHPT). Before the UHPT method, NMR equipment allowed for selective measurement of specific hydrogen nuclei signals but lacked rapid measurement of carbon nuclei signals, leading to unsatisfactory resolution of hydrogen-carbon NMR signals. Additionally, it hindered the identification of chemical structures in pharmaceutical raw materials and potentially toxic drugs.

Thanks to the UHPT method, the doctors successfully distinguished carbon nuclei associated with specific hydrogen atom nuclei in a single measurement, even amid complex carbon-carbon NMR signals, achieving a signal resolution of several hertz (Hz). They used this method to analyze the structures of complex natural products like the anticancer drug dactinomycin, which comprises optical isomers of amino acids, and accurately assign the structure of the fungicide iprovicarb, a mixture of diastereoisomers.

This novel method is not only faster and more accurate than conventional approaches but also economically efficient. The UHPT method significantly reduces the measurement time needed for ultra-high field NMR equipment, achieving equivalent NMR signal resolution approximately one-fifth of the time.

As per insights, this new NMR method can become a standard analysis technique for identifying and standardizing active ingredients in the natural product bio industry. By using this method to identify the structure of partial particulate matter, which plays a crucial role when it comes to determining the efficacy and safety of drugs, it is expected to contribute significantly to the development of the natural product bio industry and address challenges in drug development processes.

Previous Post

Breakthrough Cell & Gene Therapies To Transform Healthcare

Next Post

Combating Antibiotic Resistance With AI & Machine Learning

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Combating Antibiotic Resistance With AI & Machine Learning

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In